<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>nelfinavir</title><link>http://www.unboundmedicine.com/medline/ebm/research/nelfinavir</link><description>Unbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.</description><language>en-us</language><copyright>Unbound Medicine, Inc.</copyright><item><title>CYP2C19 Genetic Variants Affect Nelfinavir Pharmacokinetics and Virologic Response in HIV-1-Infected Children Receiving Highly Active Antiretroviral Therapy.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19890215/full_citation/CYP2C19_Genetic_Variants_Affect_Nelfinavir_Pharmacokinetics_and_Virologic_Response_in_HIV_1_Infected_Children_Receiving_Highly_Active_Antiretroviral_Therapy_</link><description>Saitoh A, Capparelli E, Aweeka F, et al. <br/><span class="title">CYP2C19 Genetic Variants Affect Nelfinavir Pharmacokinetics and Virologic Response in HIV-1-Infected Children Receiving Highly Active Antiretroviral Therapy. [JOURNAL ARTICLE]</span><br/><span class="source" title="Journal of acquired immune deficiency syndromes (1999)">J Acquir Immune Defic Syndr 2009 Nov 3.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19890215/abstract/CYP2C19_Genetic_Variants_Affect_Nelfinavir_Pharmacokinetics_and_Virologic_Response_in_HIV_1_Infected_Children_Receiving_Highly_Active_Antiretroviral_Therapy_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19890215/full_citation/CYP2C19_Genetic_Variants_Affect_Nelfinavir_Pharmacokinetics_and_Virologic_Response_in_HIV_1_Infected_Children_Receiving_Highly_Active_Antiretroviral_Therapy_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19890215/CYP2C19_Genetic_Variants_Affect_Nelfinavir_Pharmacokinetics_and_Virologic_Response_in_HIV_1_Infected_Children_Receiving_Highly_Active_Antiretroviral_Therapy_">Find Related Articles</a> </description></item><item><title>Effects of obesity induced by high-fat diet on the pharmacokinetics of nelfinavir, a HIV protease inhibitor, in laboratory rats.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19862765/full_citation/Effects_of_obesity_induced_by_high_fat_diet_on_the_pharmacokinetics_of_nelfinavir_a_HIV_protease_inhibitor_in_laboratory_rats_</link><description>Sugioka N, Haraya K, Fukushima K, et al. <br/><span class="title">Effects of obesity induced by high-fat diet on the pharmacokinetics of nelfinavir, a HIV protease inhibitor, in laboratory rats. [JOURNAL ARTICLE]</span><br/><span class="source" title="Biopharmaceutics &amp; drug disposition">Biopharm Drug Dispos 2009 Oct 27.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19862765/abstract/Effects_of_obesity_induced_by_high_fat_diet_on_the_pharmacokinetics_of_nelfinavir_a_HIV_protease_inhibitor_in_laboratory_rats_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19862765/full_citation/Effects_of_obesity_induced_by_high_fat_diet_on_the_pharmacokinetics_of_nelfinavir_a_HIV_protease_inhibitor_in_laboratory_rats_">Full Citation</a></description></item><item><title>EMS in Viracept-The course of events in 2007 and 2008 from the non-clinical safety point of view.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19857794/full_citation/EMS_in_Viracept_The_course_of_events_in_2007_and_2008_from_the_non_clinical_safety_point_of_view_</link><description>Müller L, Singer T <br/><span class="title">EMS in Viracept-The course of events in 2007 and 2008 from the non-clinical safety point of view. [JOURNAL ARTICLE]</span><br/><span class="source" title="Toxicology letters">Toxicol Lett 2009 Nov 12; 190(3):243-247.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19857794/abstract/EMS_in_Viracept_The_course_of_events_in_2007_and_2008_from_the_non_clinical_safety_point_of_view_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19857794/full_citation/EMS_in_Viracept_The_course_of_events_in_2007_and_2008_from_the_non_clinical_safety_point_of_view_">Full Citation</a></description></item><item><title>High Molecular Weight Form of Adiponectin in Antiretroviral Drug-induced Dyslipidemia in HIV-Infected Japanese Individuals Based on in vivo and in vitro Analyses.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19834271/full_citation/High_Molecular_Weight_Form_of_Adiponectin_in_Antiretroviral_Drug_induced_Dyslipidemia_in_HIV_Infected_Japanese_Individuals_Based_on_in_vivo_and_in_vitro_Analyses_</link><description>Minami R, Yamamoto M, Takahama S, et al. <br/><span class="title">High Molecular Weight Form of Adiponectin in Antiretroviral Drug-induced Dyslipidemia in HIV-Infected Japanese Individuals Based on in vivo and in vitro Analyses. [Journal Article]</span><br/><span class="source" title="Internal medicine (Tokyo, Japan)">Intern Med 2009; 48(20):1799-875.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19834271/abstract/High_Molecular_Weight_Form_of_Adiponectin_in_Antiretroviral_Drug_induced_Dyslipidemia_in_HIV_Infected_Japanese_Individuals_Based_on_in_vivo_and_in_vitro_Analyses_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19834271/full_citation/High_Molecular_Weight_Form_of_Adiponectin_in_Antiretroviral_Drug_induced_Dyslipidemia_in_HIV_Infected_Japanese_Individuals_Based_on_in_vivo_and_in_vitro_Analyses_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19834271/High_Molecular_Weight_Form_of_Adiponectin_in_Antiretroviral_Drug_induced_Dyslipidemia_in_HIV_Infected_Japanese_Individuals_Based_on_in_vivo_and_in_vitro_Analyses_">Find Related Articles</a> </description></item><item><title>The effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19773542/full_citation/The_effect_of_rifampin_and_nelfinavir_on_the_metabolism_of_methadone_and_buprenorphine_in_primary_cultures_of_human_hepatocytes_</link><description>Moody DE, Fang WB, Lin SN, et al. <br/><span class="title">The effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytes. [JOURNAL ARTICLE]</span><br/><span class="source" title="Drug metabolism and disposition: the biological fate of chemicals">Drug Metab Dispos 2009 Sep 22.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19773542/abstract/The_effect_of_rifampin_and_nelfinavir_on_the_metabolism_of_methadone_and_buprenorphine_in_primary_cultures_of_human_hepatocytes_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19773542/full_citation/The_effect_of_rifampin_and_nelfinavir_on_the_metabolism_of_methadone_and_buprenorphine_in_primary_cultures_of_human_hepatocytes_">Full Citation</a></description></item><item><title>Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: Nelfinavir.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19773109/full_citation/Contribution_and_limit_of_the_model_of_perfused_cotyledon_to_the_study_of_placental_transfer_of_drugs__Example_of_a_protease_inhibitor_of_HIV:_Nelfinavir_</link><description>Gavard L, Beghin D, Forestier F, et al. <br/><span class="title">Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: Nelfinavir. [JOURNAL ARTICLE]</span><br/><span class="source" title="European journal of obstetrics, gynecology, and reproductive biology">Eur J Obstet Gynecol Reprod Biol 2009 Sep 19.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19773109/abstract/Contribution_and_limit_of_the_model_of_perfused_cotyledon_to_the_study_of_placental_transfer_of_drugs__Example_of_a_protease_inhibitor_of_HIV:_Nelfinavir_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19773109/full_citation/Contribution_and_limit_of_the_model_of_perfused_cotyledon_to_the_study_of_placental_transfer_of_drugs__Example_of_a_protease_inhibitor_of_HIV:_Nelfinavir_">Full Citation</a> | <a href="http://linkinghub.elsevier.com/retrieve/pii/S0301-2115(09)00496-5">Publisher Full Text</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19773109/Contribution_and_limit_of_the_model_of_perfused_cotyledon_to_the_study_of_placental_transfer_of_drugs__Example_of_a_protease_inhibitor_of_HIV:_Nelfinavir_">Find Related Articles</a> </description></item><item><title>Prevention of Mother-to-Child Transmission of HIV-1 Through Breastfeeding by Treating Mothers With Triple Antiretroviral Therapy in Dar es Salaam, Tanzania: The Mitra Plus Study.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19730269/full_citation/Prevention_of_Mother_to_Child_Transmission_of_HIV_1_Through_Breastfeeding_by_Treating_Mothers_With_Triple_Antiretroviral_Therapy_in_Dar_es_Salaam_Tanzania:_The_Mitra_Plus_Study_</link><description>Kilewo C, Karlsson K, Ngarina M, et al. <br/><span class="title">Prevention of Mother-to-Child Transmission of HIV-1 Through Breastfeeding by Treating Mothers With Triple Antiretroviral Therapy in Dar es Salaam, Tanzania: The Mitra Plus Study. [JOURNAL ARTICLE]</span><br/><span class="source" title="Journal of acquired immune deficiency syndromes (1999)">J Acquir Immune Defic Syndr 2009 Aug 27.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19730269/abstract/Prevention_of_Mother_to_Child_Transmission_of_HIV_1_Through_Breastfeeding_by_Treating_Mothers_With_Triple_Antiretroviral_Therapy_in_Dar_es_Salaam_Tanzania:_The_Mitra_Plus_Study_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19730269/full_citation/Prevention_of_Mother_to_Child_Transmission_of_HIV_1_Through_Breastfeeding_by_Treating_Mothers_With_Triple_Antiretroviral_Therapy_in_Dar_es_Salaam_Tanzania:_The_Mitra_Plus_Study_">Full Citation</a></description></item><item><title>Signaling pathways in adenoid cystic cancers: Implications for treatment.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19729990/full_citation/Signaling_pathways_in_adenoid_cystic_cancers:_Implications_for_treatment_</link><description>Gupta AK, Wilke WW, Taylor EN, et al. <br/><span class="title">Signaling pathways in adenoid cystic cancers: Implications for treatment. [JOURNAL ARTICLE]</span><br/><span class="source" title="Cancer biology &amp; therapy">Cancer Biol Ther 2009 Oct 22; 8(20)</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19729990/abstract/Signaling_pathways_in_adenoid_cystic_cancers:_Implications_for_treatment_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19729990/full_citation/Signaling_pathways_in_adenoid_cystic_cancers:_Implications_for_treatment_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19729990/Signaling_pathways_in_adenoid_cystic_cancers:_Implications_for_treatment_">Find Related Articles</a> </description></item><item><title>Resistance Mechanism revealed by Crystal Structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19720046/full_citation/Resistance_Mechanism_revealed_by_Crystal_Structures_of_unliganded_nelfinavir_resistant_HIV_1_protease_non_active_site_mutants_N88D_and_N88S_</link><description>Bihani SC, Das A, Prashar V, et al. <br/><span class="title">Resistance Mechanism revealed by Crystal Structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S. [JOURNAL ARTICLE]</span><br/><span class="source" title="Biochemical and biophysical research communications">Biochem Biophys Res Commun 2009 Aug 28.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19720046/abstract/Resistance_Mechanism_revealed_by_Crystal_Structures_of_unliganded_nelfinavir_resistant_HIV_1_protease_non_active_site_mutants_N88D_and_N88S_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19720046/full_citation/Resistance_Mechanism_revealed_by_Crystal_Structures_of_unliganded_nelfinavir_resistant_HIV_1_protease_non_active_site_mutants_N88D_and_N88S_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19720046/Resistance_Mechanism_revealed_by_Crystal_Structures_of_unliganded_nelfinavir_resistant_HIV_1_protease_non_active_site_mutants_N88D_and_N88S_">Find Related Articles</a> </description></item><item><title>The history of antiretrovirals: key discoveries over the past 25 years.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19714702/full_citation/The_history_of_antiretrovirals:_key_discoveries_over_the_past_25_years_</link><description>De Clercq E <br/><span class="title">The history of antiretrovirals: key discoveries over the past 25 years. [JOURNAL ARTICLE]</span><br/><span class="source" title="Reviews in medical virology">Rev Med Virol 2009 Aug 27; 19(5):287-299.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19714702/abstract/The_history_of_antiretrovirals:_key_discoveries_over_the_past_25_years_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19714702/full_citation/The_history_of_antiretrovirals:_key_discoveries_over_the_past_25_years_">Full Citation</a></description></item></channel></rss>